Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.
Hemasphere. 2020 Sep 23;4(5):e480. doi: 10.1097/HS9.0000000000000480. eCollection 2020 Oct.
Hemasphere. 2020.
PMID: 33062947
Free PMC article.
Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Fedorova LV, Lepik KV, Volkov NP, Kotselyabina PV, Borzenkova ES, Popova MO, Beynarovich AV, Baykov VV, Kozlov AV, Moiseev IS, Mikhailova NB, Kulagin AD.
Fedorova LV, et al. Among authors: beynarovich av.
Int J Clin Oncol. 2022 Mar;27(3):626-632. doi: 10.1007/s10147-021-02085-6. Epub 2021 Nov 26.
Int J Clin Oncol. 2022.
PMID: 34826011
Free PMC article.
Item in Clipboard
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
Beynarovich A, Lepik K, Mikhailova N, Borzenkova E, Volkov N, Moiseev I, Zalyalov Y, Kondakova E, Kozlov A, Stelmakh L, Pirogova O, Zubarovskaya L, Kulagin A, Afanasyev B.
Beynarovich A, et al.
Int J Hematol. 2022 Sep;116(3):401-410. doi: 10.1007/s12185-022-03355-3. Epub 2022 May 5.
Int J Hematol. 2022.
PMID: 35511399
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.